Previous 10 | Next 10 |
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: TIDES USA 2022: Oligonucleotide and Peptide Therapeutics – May 9-12, 2022 Title: Arrowhead’s Approach to Oligonucleotide Scale-...
The following slide deck was published by Arrowhead Pharmaceuticals, Inc. in conjunction with this event. For further details see: Oligonucleotide-Based Therapeutics Conference
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a pulmonary research & development (R&D) day to discuss its emerging pipeline of pulmonary targeted RNA interference (RNAi) therapeutic candidates from 10:00 a.m. to 1:00 p.m. ET on May 26, 2022, in ...
Arrowhead Pharmaceuticals (NASDAQ:ARWR) said it dosed the first patients in a phase 2 trial of ARO-ANG3 to treat patients with homozygous familial hypercholesterolemia (HoFH). Familial hypercholesterolemia (FH) is a disorder in which people have elevated low-density lipoprotein (LDL) cho...
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patients in the Phase 2 GATEWAY clinical study of investigational ARO-ANG3 for the treatment of patients with homozygous familial hypercholesterolemia (HoFH). ARO-ANG3 is the company’s inves...
— Visirna Therapeutics, the Joint Venture formed by Arrowhead and Vivo, received an exclusive license in Greater China to four of Arrowhead’s RNAi-based investigational cardiometabolic medicines — Vivo provided an initial investment of $60 million into Visirna ...
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 10, 2022, at 4:30 p.m. ET to discuss its financial results for the fiscal 2022 second quarter ended March 31, 2022. Conference Call and Webcast Details Invest...
Yes, the MMs must have such forecasts, adjusted minute-by-minute each trading day by their upstairs desks’ direct-wire connections to trading desks at billion-$ institutional portfolios. Those forecasts are integral to hedging protections for MMs as they must short shares for a...
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: 31 st Conference of the Asian Pacific Association for the Study of the Liver (APASL 2022) – March 30-April 3, 2022 Title: Pharmaco...
My portfolio, built specifically for my retirement ~20+ years from now, experiences some major shifts as I play for upside in oil and a big biotech trade. Making monthly contributions, even though they seem small at the time, makes all the difference in the world over time in helping ...
News, Short Squeeze, Breakout and More Instantly...
Arrowhead Pharmaceuticals Inc. Company Name:
ARWR Stock Symbol:
NASDAQ Market:
Arrowhead Pharmaceuticals Inc. Website:
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 8, 2024, at 4:30 p.m. ET to discuss its financial results for the fiscal third quarter ended June 30, 2024. Webcast and Conference Call and Details Investors may ac...
– Based on promising results in the Phase 2 MUIR clinical study, the Phase 3 CAPITAN trial is designed to enroll patients with mixed hyperlipidemia and residual risk of atherosclerotic cardiovascular disease – CAPITAN builds upon existing SUMMIT program of pivotal Phase 3 clinical...
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that preclinical data on ARO-INHBE, an investigational RNAi-based medicine for the treatment of obesity and metabolic diseases, were presented at the American Diabetes Association (ADA) 84 th Scientific Sessions, which were held J...